What Analysts Are Saying About Haemonetics Stock
Portfolio Pulse from Benzinga Insights
Haemonetics (NYSE:HAE) has been analyzed by four analysts, showing a range of ratings from bullish to indifferent. The average 12-month price target is $107.5, with a high of $125 and a low of $85. Recent analyst actions include a buy rating from BTIG, a neutral rating from Citigroup, and outperform ratings from JMP Securities and Barrington Research. Haemonetics has shown a revenue growth rate of 7.98% and strong financial metrics, including a net margin of 11.41% and a ROE of 4.11%.
September 10, 2024 | 2:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Haemonetics has received mixed analyst ratings, with a recent average price target of $107.5. The company's strong financial performance, including a 7.98% revenue growth and a net margin of 11.41%, supports a positive outlook.
The mixed analyst ratings, with a majority leaning towards bullish or outperform, suggest a positive sentiment. The company's strong financial metrics, such as high net margin and ROE, further support a likely positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100